Antidepressant and antipsychotic drugs differentially affect PON1 enzyme activity. (16th June 2014)

• Record Type: Journal Article
• Authors: Avcikurt, Ayla Solmaz; Sinan, Selma; Kockar, Feray
• Is Part Of: Journal of enzyme inhibition and medicinal chemistry. Volume 30:Number 2(2015:Apr.)
• Page Start: 245
• Page End: 249
• Publication Date: 2014-06-16
• Subjects: Antidepressant -- antipsychotic -- IC50 -- inhibition -- paraoxonase -- purification; Enzyme inhibitors -- Periodicals; Enzyme Inhibitors -- periodicals; Biochemistry -- periodicals; 572.7
• DOI: 10.3109/14756366.2014.913038
• Languages: English
• ISSNs: 1475-6366

Abstract

Abstract: Human serum paraoxonase (PON1, EC 3.1.8.1.) is a high-density lipid (HDL)-associated, calcium-dependent enzyme. In this study, the effects of Haloperidol, Fluoxetine hydrochloride, Diazepam and Acepromazine drugs used for the therapy of antidepressant and antipsychotic diseases, on paraoxonase enzyme activity was studied in in vitro inhibition studies on purified human serum PON1. PON1 enzyme was purified from human blood using two-step procedures, namely, ammonium sulfate precipitation and sepharose-4B-l-tyrosine-1-napthylamine hydrophobic interaction chromatography. The overall purification of human serum PON1 was obtained in a activity of 109.29 U/mL and this enzyme was purified 125-fold. The SDS–polyacrylamide gel electrophoresis of the enzyme indicates a single band with an apparent MW of 43 kDa. Inhibition studies indicated that haloperidol and fluoxetine hydrocloride were effective inhibitors on purified human serum PON1 activity with IC50 of 0.187 and 3.08 mM values, respectively. The kinetics of interaction of haloperidol and fluoxetine hydrocloride with the purified human serum PON1 indicated uncompetitive inhibiton pattern with K i of 4.15 and 0.007 mM, respectively.